On August 27, 2025, BioNTech SE and Pfizer Inc. announced that their COVID-19 vaccine, COMIRNATY® LP.8.1, received FDA approval for adults aged 65 and older, and ages 5 to 64 with high-risk conditions. This is a significant event for the company, reflecting positively on their vaccine development efforts.